Figure 4.

A-C) White blood cell (WBC) counts, red blood cell (RBC) counts, and platelet (PLT) counts of mice bearing H82 xenografts who received [¹⁷⁷Lu]Lu-DTPA-CHX-A”-SC16. Complete blood count analyses were performed once a week on a subset of the animals used in the survival study (n=3–4). Twenty parameters were recorded, and three are represented. Values are represented as means with error bars indicating SD. Grey boxes indicate the mean ± SD of values collected from the entire cohort of H82-bearing mice two days prior to therapy administration. Grey dotted lines indicate the healthy range for female athymic mice. D-F) White blood cell (WBC) counts, red blood cell (RBC) counts, and platelet (PLT) counts of mice bearing Lu149 xenografts who received [¹⁷⁷Lu]Lu-DTPA-CHX-A”-SC16. Complete blood count analyses were performed once a week on a subset of the animals used in the survival study (n=3–4). Twenty parameters were recorded, and three are represented. Values are represented as means with error bars indicating SD. Grey boxes indicate the mean ± SD of values collected from the entire cohort of Lu149-bearing mice two days prior to therapy administration. Grey dotted lines indicate the healthy range for female athymic mice. H-I) Box plots of the terminal alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin serum levels from H82-bearing mice used in the survival study. Multiple t-tests were performed comparing each radiotherapy cohort to saline, and no significant differences were found (n=4–7). J-L) Box plots of the terminal alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin serum levels from Lu149-bearing mice used in the survival study. Multiple t-tests were performed comparing each radiotherapy cohort to saline (n=5–10; ** p-value = 0.0044 and 0.0067 for 250 and 500 μCi [¹⁷⁷Lu]Lu-DTPA-CHX-A”-SC16, respectively).